BioCryst Pharmaceuticals, Inc. has entered into a voting and support agreement with certain stockholders of Astria Therapeutics, Inc. The agreement, dated as of October 14, 2025, outlines the terms and conditions under which the stockholders agree to vote in favor of the adoption of the Merger Agreement, the Merger, and the approval of the transactions contemplated in the Merger Agreement.
As per the agreement, each stockholder has agreed to vote in favor of the adoption of the Merger Agreement and the approval of any proposal to adjourn or postpone the Company Stockholders’ Meeting to a later date if there are not sufficient votes for adoption of the Merger Agreement on the date of the meeting. They have also agreed to vote against any Acquisition Proposal or any acquisition agreement related to such Acquisition Proposal and any election of new directors to the Board of Directors, among other actions.
Additionally, the agreement includes provisions related to the ownership of Subject Shares, voting arrangements, and the absence of litigation against the stockholders that could impair their ability to perform their obligations.
The press release does not provide specific financial metrics or changes since the last period. Following these announcements, the company's shares moved 1.93%, and are now trading at a price of $8.47. Check out the company's full 8-K submission here.
